CHIRON CORPORATION
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 1981-01-01
- Employees
- 5.4K
- Market Cap
- -
- Website
- http://www.chiron.com/
Clinical Trials
11
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)β’ Click on a phase to view related trials
Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine
- Conditions
- Meningococcal Disease; Meningococcal Meningitis
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2005-12-06
- Lead Sponsor
- Chiron Corporation
- Target Recruit Count
- 264
- Registration Number
- NCT00262015
- Locations
- π¬π§
University of Oxford, The Oxford Vaccine Group, Oxford, United Kingdom
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Non-Hodgkin Lymphoma
- First Posted Date
- 2005-01-07
- Last Posted Date
- 2006-02-06
- Lead Sponsor
- Chiron Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT00100737
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer
- Conditions
- Esophageal NeoplasmsStomach NeoplasmsAdenocarcinoma
- First Posted Date
- 2003-02-13
- Last Posted Date
- 2006-07-11
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00054873
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈACRC/Arizona Clinical Research Center, Tucson, Arizona, United States
πΊπΈGlendale Memorial Hospital, Glendale, California, United States
Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2003-01-16
- Last Posted Date
- 2006-07-11
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00051688
- Locations
- πΊπΈ
ACRC/Arizona Clinical Research Center, Tucson, Arizona, United States
πΊπΈUSC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈComprehensive Cancer Centers of the Desert, Palm Springs, California, United States
Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
- Conditions
- Lymphoma, Non-Hodgkin
- First Posted Date
- 2002-09-16
- Last Posted Date
- 2006-02-06
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00045864
- Locations
- πΊπΈ
ACRC/Arizona Clinical Research Center, Inc., Tucson, Arizona, United States
πΊπΈHoag Cancer Center, Newport Beach, California, United States
πΊπΈUC Davis Cancer Center, Sacramento, California, United States
- Prev
- 1
- 2
- 3
- Next